Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry by Kraft, Magdalena et al.
Allergy. 2019;00:1–10.	 	 	 | 	1wileyonlinelibrary.com/journal/all
 
Received:	1	June	2019  |  Revised:	9	August	2019  |  Accepted:	22	August	2019
DOI: 10.1111/all.14069  
O R I G I N A L  A R T I C L E
Epidemiology and Genetics
Secondary prevention measures in anaphylaxis patients: Data 
from the anaphylaxis registry
Magdalena Kraft1  |   Macarena Pia Knop2 |   Jean‐Marie Renaudin3 |   Kathrin Scherer 
Hofmeier4 |   Claudia Pföhler5 |   Maria Beatrice Bilò6,7 |   Roland Lang8 |   
Regina Treudler9 |   Nicola Wagner10 |   Thomas Spindler11 |   Jonathan O'B Hourihane12 |   
Ioana Maris13 |   Alice Koehli14 |   Andrea Bauer15 |   Lars Lange16  |   Sabine Müller17 |   
Nikolaos G. Papadopoulos18,19 |   Bettina Wedi20  |   Anne Moeser21 |   Luis F. Ensina22 |   
Montserrat Fernandez‐Rivas23,24 |   Ewa Cichocka‐Jarosz25 |   George Christoff26,27 |   Blanca 
E. Garcia28 |   Iwona Poziomkowska‐Gęsicka29 |   Victoria Cardona24,30  |   Tihomir 
B. Mustakov31 |   Uta Rabe32 |   Vera Mahler33 |   Linus Grabenhenrich1,34 |   Sabine Dölle‐




















































































The	 identification,	 consequent	 avoidance	 of	 triggers,	 and	 specific	
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2  | PATIENTS AND METHODS
2.1 | Database
The	Anaphylaxis	Registry	 is	 a	 real-life	database	 that	 collects	data	 re-
garding	 moderate	 and	 severe	 anaphylactic	 reactions.	 The	 registry	
was	described	elsewhere.10-12	One	hundred	and	 thirty-seven	special-
ized	 tertiary	allergy	centers	 from	eleven	countries	 (Germany,	Austria,	
Switzerland,	Poland,	Italy,	Spain,	Ireland,	Greece,	France,	Bulgaria,	and	


















The	scope	of	 the	 registry	 is	moderate	and	severe	anaphylactic	
reactions;	however,	it	contains	a	small	proportion	of	cases	with	mild	
anaphylactic	 symptoms,	 which	 were	 excluded	 from	 the	 analysis	









1. What prophylactic measures have been instigated following the 
episode?	 The	 answers’	 options	 (multiple	 selections	 possible)	
were	 as	 follows:	 “Counseling	 about	 avoidance	 of	 the	 trigger,”	
“Prescription	 of	 emergency	 drugs,”	 “Training	 in	 emergency	
management	plan,	 including	drug	training,”	“SIT,”	and	“Others”	
(with	 an	 option	 to	 describe	 a	 measure	 in	 a	 free	 text	 form).	
For	 each	 measure,	 the	 time	 point	 of	 the	 introduction	 was	
asked	as	follows	(multiple	selections	possible):	“Already	in	place	
prior	 to	 reaction,”	 “At	 the	 emergency	 department/	 primary	
care	 prior	 to	 discharge,”	 “In	 primary	 care	 during	 a	 follow-up	
visit,”	 and	 “In	 specialist	 center	 during	 a	 follow-up	 visit.”
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2. What kind of emergency drugs were prescribed following the recov-
ery of the reaction?	Here,	the	multiple	selections	of	the	following	
medication	were	 offered:	 “Adrenaline	 autoinjector,”	 “Adrenaline	
inhaler,”	 “Antihistamines,”	 “β2-mimetics,”	 “Corticosteroids,”	 and	
“Other”	(free	text	possible).	The	time	point	of	the	prescription	was	
asked	as	described	for	the	question	mentioned	above.
3.	 Beginning	 with	 version	 7.0	 of	 the	 questionnaire	 (since	 March	
2017;	 597	 cases	 in	 our	 dataset	were	 reported	 during	 this	 time	
period)	 the	 following	 additional	 information	 was	 asked:	Which 
adrenaline autoinjector was prescribed? How many adrenaline auto-















described	 in	 the	 figure	 legends).	 In	77%	of	 the	cases,	 SIT	was	 ini-
tiated.	Most	patients	 in	 this	group	were	prescribed	adrenaline	au-
toinjector	 (95%),	 antihistamines	 (97%),	 and	 corticosteroids	 (95%;	
Figure	1B).
Among	 patients	 with	 food	 allergy,	 trigger	 avoidance	 counsel-
ing	was	 the	most	 frequent	preventive	measure	 (98%),	 followed	by	


































Trigger avoidance couns. Emergency drugs












































Trigger avoidance couns. Emergency drugs
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emergency	 drug	 prescription	 (95%)	 and	 emergency	 management	
training	 (95%;	 Figure	 1A).	Moreover,	 SIT	 was	 initiated	 in	 2.5%	 of	
these	 patients.	 Special	 extensive	 training	 programs	 and	 individual	
nutritional	counseling	were	offered	in	a	few	cases.	Patients	with	food	
allergy	 were	 less	 likely	 to	 receive	 an	 adrenaline	 autoinjector	 pre-
scription	than	those	with	venom	allergy	(85%	vs	95%).	Furthermore,	




Interestingly,	 despite	 that	 in	 case	 of	 drug	 allergy	 the	 identi-
fied	 allergen	 can	 be	 avoided	without	 a	 great	 risk	 of	 accidental	
intake,	 40%	 of	 these	 patients	 received	 emergency	 medication	
prescribed,	 particularly	 antihistamines	 and/or	 corticosteroids;	






To	 investigate	 which	 factors	 have	 an	 influence	 on	 the	 sec-
ondary	prevention	measures	offered,	we	performed	the	analysis	






Austria,	 Germany,	 Ireland,	 and	 Switzerland	 n	 =	 4079).	 Here,	 we	
observed	that	babies	 (n	=	61)	and	the	elderly	 (>80	years,	n	=	29)	
received	less	emergency	medication,	and	particularly	fewer	auto-
injectors	prescribed	 (approximately	70%	of	 the	patients	 in	 these	





A) At all (after or during the visits 
in a specialized allergy center)
B) Before visit in a special‐
ized allergy center
Number of observations n = 3608 n = 4410
 Odds ratio [95%‐CI] P‐value
Odds ratio 
[95%‐CI] P‐value
Male	sex 1.13	[0.92-1.39] .233 0.94	[0.78-1.15] .593
Age	(in	years) 0.98	[0.98-0.99] <.001 0.98	[0.98-0.99] <.001
Elicitor	(vs	venom)








1.38	[0.88—2.17] .159 1.12	[0.97-1.3] .130
Asthma 1.25	[0.92-1.7] .153 1.22	[0.99-1.5] .068
Mastocytosis 3.03	[1.26-7.28] .036 1.53	[0.99-2.36] .053
Severity	grade	III	or	IV	(vs	
grade	IIb)




0.53	[0.31-0.91] .02 0.44	[0.148-1.3] .135
Brazil	as	country	of	
residence
0.11	[0.08-0.16] <.001 Omittedd  




















3.2 | The majority of patients with anaphylaxis 
were offered adequate prophylaxis measures for the 




















antihistamines	 (37%)	and	corticosteroids	 (32%)	 than	an	adrenaline	
autoinjector	(27%).










tients	 in	specialized	centers	 is	high.	However,	before	the	visit	 to	a	
center	less	than	half	of	the	patients	were	offered	adequate	prophy-
laxis	to	handle	the	next	reaction.
3.3 | Eighty‐four percent of the patients with an 
absolute indication for an adrenaline autoinjector 
according to EAACI guidelines were prescribed one
The	EAACI	guidelines	defined	six	groups	of	patients	with	an	abso-
lute	indication	for	an	adrenaline	autoinjector:	history	of	food,	latex,	
or	 aeroallergens	 anaphylaxis	 (a);	 exercise-induced	 anaphylaxis	 (b);	
idiopathic	 anaphylaxis	 (c);	 coexisting	 asthma	 and	 food	 allergy	 (d);	
venom	allergy	without	receiving	SIT	(e);	and	venom	allergy	and	mast	
cell	 disorder	 (f).	 In	 our	 dataset,	 4032	 cases	 fulfilled	 one	 of	 these	
criteria.	The	information	on	adrenaline	autoinjector	prescription	was	
provided	 in	3817	cases.	Of	 these,	84%	were	prescribed	an	adren-
aline	 autoinjector	 (before	or	 during	 a	 consultation	 in	 a	 specialized	
center;	Figure	2A).	Guideline	adherence	was	very	good	in	patients	
















3.4 | Patients from countries without 




countries	 contributing	 to	 the	 registry,	 autoinjectors	 are	 not	 reim-
bursed	in	Poland,	Bulgaria,	and	Brazil.	Moreover,	in	Brazil	autoinjec-
tors	 are	 not	 available	 at	 local	 pharmacies	 and	have	 to	 be	ordered	
from	specialized	companies.	This	situation	was	reflected	in	our	data,	
as	patients	from	Brazil	received	notably	less	adrenaline	autoinjector	
prescriptions	 than	 patients	 from	other	 countries	 (38%	 (n	 =	 48)	 vs	
79%	 (n	 =	 163)	 in	 European	 countries	without	 reimbursement	 and	
85%	(n	=	3607)	in	European	countries	with	reimbursement;	data	not	
shown).
3.5 | Elicitor and severity of the reaction, 
age of the patient, mastocytosis as comorbidity, and 
reimbursement/availability of the autoinjector 
influence physician's decision to prescribe one






































main	 source	 of	 bias	may	 be	 the	 definition	 of	 particular	measures,	
such	as	 “counseling	about	avoidance	of	 the	 trigger”	or	 “training	 in	
emergency	 management	 plan,	 including	 drug	 training”	 that	 can	















Prescription of the adrenaline autoinjector following the EAACI guide-





Prescription of the adrenaline autoinjector following the EAACI















































































































































































































of	 the	 children	 were	 prescribed	 an	 autoinjector.	 Another	 popula-
tion-based	 study	 conducted	 in	Canada	 reported	 that	 45%-55%	of	
patients	with	food	allergy	have	an	autoinjector.17















imbursement	of	 the	autoinjector	 (no	by	chance	 the	 two	European	
countries	from	the	registry	without	reimbursement	are	also	the	ones	
with	the	lowest	gross	domestic	income)	were	present	and	significant	
in	 the	multivariate	 analysis;	 however,	 the	 differences	were	 not	 as	
notable	 as	 expected.	This	 can	be	partially	 related	 to	 the	 fact	 that	
our	 collaborating	 centers	 in	 the	 countries	without	 reimbursement	
are	mainly	placed	in	big	cities;	therefore,	they	may	attract	a	selected,	
higher-income	population.	On	the	other	hand,	we	have	no	informa-





preventive	measures	 offered	 to	 them.	 Two	 groups	 received	 auto-
injector	 prescriptions	 less	 frequently:	 babies	 and	 elderly	 patients	











emphasis	 on	 special	 needs	 of	 children.	 In	 this	 case,	 the	 European	
Medicines	Agency	(EMA)	recommendations	to	prescribe	additional	
adrenaline	autoinjector	 for	 the	use	 in	 the	 school	might	have	been	
crucial.
Overall,	our	data	highlight	the	importance	of	specialized	allergy	
centers	 and	 allergists	 in	 terms	 of	 providing	 adequate	 secondary	
prevention	 measures	 to	 individuals	 with	 anaphylaxis.	 Healthcare	
standards,	except	 for	 those	of	 specialized	 facilities,	were	 found	 to	
be	insufficient	as	in	most	cases	the	international	guidelines	were	not	
followed.	 This	 implicates	 the	 requirement	 of	 better	 education	 for	
emergency	doctors	and	primary	healthcare	providers	to	emphasize	
the	 importance	of	 the	 secondary	prevention	measures	 in	 anaphy-
laxis	patients.
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